Vaccine Contract Manufacturing Market 2024 | Market Size, Key Drivers, Industry Developments, Share, Future Growth Prospects and Forecast To 2033
The Vaccine Contract Manufacturing
Global Market Report 2024 by The Business Research Company provides market
overview across 60+ geographies in the seven regions - Asia-Pacific, Western
Europe, Eastern Europe, North America, South America, the Middle East, and
Africa, encompassing 27 major global industries. The report presents a
comprehensive analysis over a ten-year historic period (2010-2021) and extends
its insights into a ten-year forecast period (2023-2033).
Learn More On The Vaccine
Contract Manufacturing Market:
According to The Business Research
Company’s Vaccine Contract Manufacturing Global Market Report 2024, The vaccine
contract manufacturing market size has grown strongly in recent years. It will
grow from $3.3 billion in 2023 to $3.62 billion in 2024 at a compound annual
growth rate (CAGR) of 9.9%. The growth in the historic period can be
attributed to traditional vaccine manufacturing limitations, global disease
outbreaks driving vaccine demand, regulatory support for contract
manufacturing, increasing complexity of vaccine production, surge in vaccine
research and development..
The vaccine contract manufacturing
market size is expected to see rapid growth in the next few years. It will grow
to $5.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be
attributed to growing emphasis on pandemic preparedness, increased outsourcing
in pharmaceutical manufacturing, expansion of biopharmaceutical companies,
accelerated vaccine development timelines, global initiatives for vaccine
accessibility. Major trends in the forecast period include integration of
single-use technologies in manufacturing, rise in personalized medicine
approaches to vaccine development, development of mrna and viral vector
vaccines, adoption of continuous manufacturing processes, expansion of
fill-finish services.
An increase in initiatives
favoring vaccinations is expected to propel the growth of the vaccine contract
manufacturing market going forward. Vaccination refers to an easy, safe, and
efficient method of defending against contagious diseases before they occur. It
boosts the immune system and builds up the body's defenses against infections.
Increasing initiatives favoring vaccinations would help advance and develop
various vaccine manufacturing processes to support vaccine contract
manufacturing. For instance, in November 2022, the U.S. Department of Health
and Human Services, a US-based cabinet-level executive branch department of the
federal government, announced a new $350 million initiative for HRSA (Health
Resources and Services Administration)-supported health facilities to boost the
number of COVID-19 vaccines in their communities, with an emphasis on
marginalized people. Therefore, the increase in initiatives favoring
vaccinations is driving the growth of the vaccine contract manufacturing
market.
Get A Free Sample Of The Report
(Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp
The vaccine contract
manufacturing market covered in this report is segmented –
1) By Service Type:
Fill-Finish, Bulk Product
2) By Vaccine Type:
Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid)
Vaccines, Subunit Vaccines, Toxoid-Based Vaccines
3) By Process: Downstream, Upstream
4) By Scale Of Operation:
Preclinical, Clinical, Commercial
5) By End-Use: Human Use,
Veterinary
Top Major Players
Pfizer Inc.
Johnson & Johnson
AbbVie Inc.
Sanofi
GlaxoSmithKline
Strategic partnerships are a key
trend gaining popularity in the vaccine contract manufacturing market.
Significant companies are partnering with the companies operating in the
vaccine contract manufacturing market to sustain their position in the market.
For instance, in January 2023, Vaxxas, an Australia-based biotechnology company
that develops a novel needle-free vaccination technology, partnered with the
Coalition for Epidemic Preparedness Innovations, a Norway-based foundation, to
finance and coordinate the development of new vaccines and promote the
development of Vaxxas' needle-free vaccine patch delivery technology in a
project that may eliminate the frozen storage requirement for mRNA vaccines.
Furthermore, in January 2021, Novartis AG, a Switzerland-based pharmaceutical
company operating in the vaccine contract manufacturing market, partnered with
Pfizer Inc., a US-based pharmaceutical company, and BioNTech SE, a
Germany-based biotechnology company, to provide manufacturing capacity for the
Pfizer-BioNTech COVID-19 vaccine. This partnership helps Novartis take bulk
mRNA active ingredients from BioNTech and fill them into vials under aseptic
conditions for shipment back to BioNTech for distribution to the healthcare
system.
The vaccine contract
manufacturing market report table of contents includes:
1. Executive Summary
2. Vaccine Contract Manufacturing
Market Characteristics
3. Vaccine Contract Manufacturing
Market Trends And Strategies
4. Vaccine Contract Manufacturing
Market - Macro Economic Scenario
5. Global Vaccine Contract
Manufacturing Market Size and Growth
.............................
32. Global Vaccine Contract
Manufacturing Market Competitive Benchmarking
33. Global Vaccine Contract
Manufacturing Market Competitive Dashboard
34. Key Mergers And Acquisitions
In The Vaccine Contract Manufacturing Market
35. Vaccine Contract Manufacturing
Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment